ERAS
NASD Erasca, Inc.$14.21 ↓ -0.28 (-1.93%) Trading Down from the previous close of $14.49, $0.84 below the day’s high of $15.05
- YTD change
- +281.99%
- vs 20-day SMA
- -2.37%
- vs 200-day SMA
- -3.00%
Price ranges
Price & Performance
-7.79 (-34.76%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 41.9% away from all-time highs of $24.47
- ERAS is up 282% since the beginning of the year
- ERAS is up 497% over the past 12 months
- ERAS is down 9% over the past 1 month
- 12% of all ERAS investors are betting against ERAS
ERAS reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +514.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.08
- Last 5 days
- -3.86%
- vs 8-day SMA
- -3.23%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
